Kowalczyk Aleksandra, D'Souza Cheryl A, Zhang Li
Toronto General Research Institute, the University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Department of Immunology, University of Toronto, Toronto, ON, Canada.
Eur J Immunol. 2014 Apr;44(4):1143-55. doi: 10.1002/eji.201343601. Epub 2014 Jan 22.
Regulatory T (Treg) cells suppress immune responses by downregulating the expression of costimulatory molecules CD80 and CD86 on dendritic cells (DCs) through cytotoxic T lymphocyte antigen 4 (CTLA4). However, it is unclear whether inducible Treg (iTreg) cells can hamper immune responses via the same mechanism. Moreover, whether a reverse signal sent by CTLA4 alone is sufficient to prevent maturation of DCs has never been evaluated. Here, we demonstrate that stimulation of DCs with CTLA4, either expressed by inducible Treg cells or by cross-linking with CTLA4Fc fusion protein, can significantly inhibit LPS-induced CD80 and CD86 mRNA and protein expression in both mouse and human DCs. Importantly, CTLA4Fc-treated DCs had reduced ability to stimulate CD4(+) and CD8(+) T-cell proliferation and cytokine production in both syngeneic and allogeneic settings. We also investigated the molecular mechanism involved in the induction of tolerogenic DCs by CTLA4. We determined that the interaction of CTLA4 with its high affinity ligand CD80 on DCs induces STAT3 phosphorylation followed by reduction of NF-κB activity, leading to suppression of CD80 and CD86 gene transcription and protein production. Our work opens new windows for the generation of tolerogenic DCs that could ultimately be used for treating autoimmune diseases and transplant rejection.
调节性T(Treg)细胞通过细胞毒性T淋巴细胞抗原4(CTLA4)下调树突状细胞(DC)上共刺激分子CD80和CD86的表达来抑制免疫反应。然而,尚不清楚诱导性Treg(iTreg)细胞是否能通过相同机制阻碍免疫反应。此外,从未评估过单独由CTLA4发出的反向信号是否足以阻止DC成熟。在此,我们证明,用诱导性Treg细胞表达的CTLA4或与CTLA4Fc融合蛋白交联刺激DC,可显著抑制小鼠和人DC中LPS诱导的CD80和CD86 mRNA及蛋白表达。重要的是,CTLA4Fc处理的DC在同基因和异基因环境中刺激CD4(+)和CD8(+) T细胞增殖及细胞因子产生的能力均降低。我们还研究了CTLA4诱导耐受性DC的分子机制。我们确定,CTLA4与其在DC上的高亲和力配体CD80相互作用诱导STAT3磷酸化,随后NF-κB活性降低,导致CD80和CD86基因转录及蛋白产生受到抑制。我们的工作为生成最终可用于治疗自身免疫性疾病和移植排斥反应的耐受性DC开辟了新途径。